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The commonest congenital CNS lesion is intraparenchymal 
melanosis, which has highly characteristic MRI features, 
and even if symptomatic does not carry a poor prognosis 
in terms of life expectancy and does not require biopsy [7]. 
However, rarer lesions cause more diagnostic uncertainty, 
and in particular, the term ‘leptomeningeal melanocytosis’ 
currently includes both stable congenital disease, and either 
newly acquired or clinically and radiologically progressive 
fatal disease [4, 7]. The problem with distinguishing benign 
from malignant leptomeningeal disease other than by 
clinical outcome has been that histological studies do not 
always demonstrate malignant morphology or leptomenin-
geal invasion of the underlying parenchyma, despite being 
ultimately fatal. Histology, however, continues to form a 
key part of any assessment, including for distinguishing 
melanoma from the very rare occurrence of other CNS 
tumours in this condition.
Seminal work on benign and malignant tumours arising 
within cutaneous CMN established that in general there is a 
difference in chromosomal copy number patterns between 
CMN, benign proliferative nodules, and cutaneous mela-
noma arising in CMN, a study which included one meta-
static CNS sample [2]. To date, however, there has been no 
published data on chromosomal copy number pattern in 
primary CNS melanoma arising in children with CMN, and 
we sought to establish the value of this test.
DNA was extracted directly from six fresh CNS biopsy 
specimens using standard methods. These samples were 
taken prospectively from all cases of suspected primary 
CNS melanoma seen in our tertiary referral service over a 
period of six years. Five were from patients with a clinico-
radiological diagnosis of newly acquired or progressive 
melanotic CNS disease, and one from a rare case of diffuse 
leptomeningeal melanocytosis which has been clinically 
only very slowly progressive, and radiologically stable 
The term ‘neurocutaneous melanosis’ was coined in 1861 
as a post-mortem description of multiple congenital mel-
anocytic naevi (CMN) and fatal diffuse leptomeningeal 
melanocytosis [5]. The congenital phenotype of this disease 
is caused by post-zygotic mutations in the gene NRAS in 
80% of cases [3], and progression to cutaneous melanoma 
involves further mutations [1, 3, 6]. We have previously 
argued that there should be a distinction made between 
congenital abnormalities of the CNS and acquired primary 
CNS melanoma [7], a situation which can be considered 
analogous to the presence of benign congenital naevi on the 
skin, and the risk of development of cutaneous melanoma. 
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Fig. 1  MRI of patient 2 demonstrating melanoma within the cerebellum (a, b) and physically unconnected diffuse leptomeningeal melanoma 
(c). Cerebellar melanoma showing multiple large gains and losses on array CGH (d)
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over 11 years after initial leptomeningeal spread during 
the first year of life. All six were NRAS codon 61 mutation 
positive, and BRAF codon 600 wild-type. In one of the six 
patients there was classical progressive diffuse melanotic 
leptomeningeal disease, without skin disease (patient 1, 
supplementary Table 1). This patient was included as the 
leptomeningeal disease was indistinguishable clinically and 
genetically from that seen in patients with CMN. Whole 
genome array comparative genomic hybridization (CGH) 
was performed using Roche Nimblegen 135K oligonucleo-
tide arrays or Affymetrix CytoScan 750K and commercial 
sex-matched pooled controls.
All five biopsies from patients with a clinico-radiolog-
ical diagnosis of CNS melanoma based on tumour behav-
ior (patients 1–5) showed large gains and/or losses of parts 
of chromosomes, with a similar pattern to known findings 
in cutaneous melanoma in CMN patients [2] (Fig. 1, sup-
plementary Tables 1 and 2), and tragically, all five children 
have succumbed to their disease. In the patient with stable 
diffuse leptomeningeal melanocytosis, however, we found 
a normal chromosomal copy number pattern and the patient 
continues to be clinically stable.
Whole genome copy number abnormalities in newly 
acquired, or clinico-radiologically progressive melanotic 
disease in the CNS seem to mirror those described in cuta-
neous melanoma, with a characteristic signature of multi-
ple gains and losses of parts of chromosomes seen in fatal 
cases even where histology was not clearly malignant. 
These can, therefore be considered as primary CNS mela-
noma. On the other hand, no copy number abnormalities 
were seen in the one case of stable leptomeningeal disease. 
This supports the use of copy number measurement as an 
adjunct to early screening MRI of the CNS to characterize 
the congenital neurological phenotype, and of NRAS and 
BRAF genotyping and histopathology where biopsies of 
suspected primary CNS melanoma are taken.
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